TG THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against TG Therapeutics, Inc.

Lead Plaintiff Deadline is December 3, 2018

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (Nasdaq: TGTX) in the United States District Court for the Southern District of New York on behalf of a class consisting of investors who purchased or otherwise acquired TG Therapeutics securities between June 4, 2018 through September 25, 2018, both dates inclusive (the “Class Period”).

Investors who have incurred losses in the shares of TG Therapeutics, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of TG Therapeutics, Inc., you may, no later than December 3, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in TG Therapeutics, Inc.

The filed Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:

• TG Therapeutics was involved in cleaning data collected from its UNITY-CLL study and was therefore able to gain an understanding of the efficacy of the combination therapy;
   
• due to the data cleaning, TG Therapeutics knew the UNITY-CLL study had failed to meet its stated goal and therefore knew it would be unable to seek accelerated approval;
   
• as a result of the foregoing, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival; and
   
• consequently, Defendants’ statements during the Class Period were materially false and misleading and/or lacked a reasonable basis at all relevant times.

As a result of these false and misleading statements, the price of TG Therapeutics common stock was inflated to as high as $14.70 per share before falling 44% on September 25, 2018, from $9.25 per share to close at $5.15 per share.

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.